![An Approach to the Patient Refractory to Platelets Transfusion](http://s1.studyres.com/store/data/006950238_1-b11c0d3c238c18fc5735515af645d269-300x300.png)
Folie 1
... the PU/UC region induced also a peak of hepatic RIG-I and ISG56 mRNA levels in WT mice,but not in RIG-I-/- mice induction of tissue-wide expression of ISG54 in WT mice suggestingthat paracrine signalling of IFN-β could play a role in hepatic defenses against HCV ...
... the PU/UC region induced also a peak of hepatic RIG-I and ISG56 mRNA levels in WT mice,but not in RIG-I-/- mice induction of tissue-wide expression of ISG54 in WT mice suggestingthat paracrine signalling of IFN-β could play a role in hepatic defenses against HCV ...
Distribution of macrophages in the human fallopian tubes: an
... other leukocyte populations, such as T lymphocytes, were identified in normal human uterine tubes by Otsuki et al. [25], Boehme and Donat [4], Hunt and Lynn [16]. These studies were based on immunolabelling and electron microscopy. Most of the evidence for mucosal immune responses in the female repr ...
... other leukocyte populations, such as T lymphocytes, were identified in normal human uterine tubes by Otsuki et al. [25], Boehme and Donat [4], Hunt and Lynn [16]. These studies were based on immunolabelling and electron microscopy. Most of the evidence for mucosal immune responses in the female repr ...
Case 2 - Ipswich-Year2-Med-PBL-Gp-2
... 20-30% of cancers are missed when only the PSA level is obtained. The sensitivity can be improved by lowering the cutoff or by monitoring PSA values so that a rise in PSA level of more than 20-25% per year or an increase of 0.75 ng/mL in a year would trigger performance of a biopsy regardless of the ...
... 20-30% of cancers are missed when only the PSA level is obtained. The sensitivity can be improved by lowering the cutoff or by monitoring PSA values so that a rise in PSA level of more than 20-25% per year or an increase of 0.75 ng/mL in a year would trigger performance of a biopsy regardless of the ...
Neuropilin 1 is expressed on thymus-derived natural
... Soyoung Oh,8 Ming O. Li,8 Rachel E. Niec,8,9 Alexander Y. Rudensky,8,9 Michael L. Dustin,1,3 Dan R. Littman,1,3,4 and Juan J. Lafaille1,3 3Department ...
... Soyoung Oh,8 Ming O. Li,8 Rachel E. Niec,8,9 Alexander Y. Rudensky,8,9 Michael L. Dustin,1,3 Dan R. Littman,1,3,4 and Juan J. Lafaille1,3 3Department ...
The Role of Donor‐Specific HLA Alloantibodies in Liver
... potential DSA-associated pathologies that all require further study, preferably as part of prospective clinical trials (Table 1). The relative contribution of antibodies to graft injury has been difficult to tease out because: (1) rejection, currently categorized as ‘‘cellular,’’ may represent a mix ...
... potential DSA-associated pathologies that all require further study, preferably as part of prospective clinical trials (Table 1). The relative contribution of antibodies to graft injury has been difficult to tease out because: (1) rejection, currently categorized as ‘‘cellular,’’ may represent a mix ...
Cell-free eukaryotic systems for the production
... lysate are exclusively used for the synthesis of a given target protein [10]. Cell extracts generated from Escherichia coli have been used for the synthesis of antibody fragments as well as antibody fragment fusion proteins [6–8, 11–13]. These lysates are usually characterized by high production yie ...
... lysate are exclusively used for the synthesis of a given target protein [10]. Cell extracts generated from Escherichia coli have been used for the synthesis of antibody fragments as well as antibody fragment fusion proteins [6–8, 11–13]. These lysates are usually characterized by high production yie ...
Medical monitoring: CD4 cell counts
... What is the CD4 count? Lymphocytes are a subgroup of the body’s white blood cells (leukocytes). CD4 cells are one type of lymphocyte and they co-ordinate the immune system’s response to certain micro-organisms, such as viruses. CD4 cells are the main cells in the body infected by HIV. HIV causes the ...
... What is the CD4 count? Lymphocytes are a subgroup of the body’s white blood cells (leukocytes). CD4 cells are one type of lymphocyte and they co-ordinate the immune system’s response to certain micro-organisms, such as viruses. CD4 cells are the main cells in the body infected by HIV. HIV causes the ...
Program - QIMR Berghofer Conferences
... (SNHL) and neurodevelopmental outcome in infants with symptomatic congenital cytomegalovirus (cCMV) infection ...
... (SNHL) and neurodevelopmental outcome in infants with symptomatic congenital cytomegalovirus (cCMV) infection ...
Influenza vaccine
... 2. Loss of expression of CD28 cell surface marker EFFROS RB et al Exp Gerontol 1994; 29: 601-9 ...
... 2. Loss of expression of CD28 cell surface marker EFFROS RB et al Exp Gerontol 1994; 29: 601-9 ...
Lymph formation, composition and circulation
... and protease inhibitors covered half of the proteome shared by the two fluids, which is suggestive of a core of conserved functional features between plasma and lymph. In 2013, Clement et al. (12, 47) reported a comparative proteomics analysis of matched human plasma versus lymph, highlighting the ...
... and protease inhibitors covered half of the proteome shared by the two fluids, which is suggestive of a core of conserved functional features between plasma and lymph. In 2013, Clement et al. (12, 47) reported a comparative proteomics analysis of matched human plasma versus lymph, highlighting the ...
Essential role of Toll-like receptor 2 in
... Received on April 30, 2011; revised on August 22, 2011; accepted on August 23, 2011 ...
... Received on April 30, 2011; revised on August 22, 2011; accepted on August 23, 2011 ...
$doc.title
... Worldwide, the heterosexual route is the most common mode of sexual transmission of HIV-‐1 and women are particularly susceptible to this infection. After penetration of the mucosal epithelium HIV-‐1 interacts ...
... Worldwide, the heterosexual route is the most common mode of sexual transmission of HIV-‐1 and women are particularly susceptible to this infection. After penetration of the mucosal epithelium HIV-‐1 interacts ...
Non-Hodgkin Lymphoma What is cancer?
... Diffuse large B-cell lymphoma (DLBCL) can affect any age group but occurs mostly in older people (the average age is mid-60s). It usually starts as a quickly growing mass in a lymph node deep inside the body, such as in the chest or abdomen, or in a lymph node that you can feel, such as in the neck ...
... Diffuse large B-cell lymphoma (DLBCL) can affect any age group but occurs mostly in older people (the average age is mid-60s). It usually starts as a quickly growing mass in a lymph node deep inside the body, such as in the chest or abdomen, or in a lymph node that you can feel, such as in the neck ...
Immuno-Isolation of Pancreatic Islet Allografts Using Pegylated
... Two major hurdles need to be surmounted for cell therapy for diabetes: (i) allo-immune rejection of grafted pancreatic islets, or stem/precursor cell-derived insulin-secreting cells; and (ii) continuing auto-immunity against the diabetogenic endogenous target antigen. Nanotherapeutics offer a novel ...
... Two major hurdles need to be surmounted for cell therapy for diabetes: (i) allo-immune rejection of grafted pancreatic islets, or stem/precursor cell-derived insulin-secreting cells; and (ii) continuing auto-immunity against the diabetogenic endogenous target antigen. Nanotherapeutics offer a novel ...
- Wiley Online Library
... cells appear to play only fine-tuning roles during wound repair, because their genetic depletion leads to almost entirely normal healing.29,30 Other immune cell lineages are less well studied and may become involved in the repair process only if it becomes chronic. Currently very little is known abo ...
... cells appear to play only fine-tuning roles during wound repair, because their genetic depletion leads to almost entirely normal healing.29,30 Other immune cell lineages are less well studied and may become involved in the repair process only if it becomes chronic. Currently very little is known abo ...
Toward a Universal Influenza Vaccine
... the presence of HA-specific Abs secreted by PBMCs correlated with the ability of lymphocytes to mediate cytotoxicity against influenza virus–infected cells. This is consistent with our recent studies showing that cross-reactive ADCC-mediating Abs against a broad range of HA and NA proteins from IAV ...
... the presence of HA-specific Abs secreted by PBMCs correlated with the ability of lymphocytes to mediate cytotoxicity against influenza virus–infected cells. This is consistent with our recent studies showing that cross-reactive ADCC-mediating Abs against a broad range of HA and NA proteins from IAV ...
Mucosal IL-17 immunity in disease 12112012
... FOXP3+ cells than did control subjects, both before and after the anti-TNF-α treatment. Intestinal interferon-γ and IL-17 mRNA expression was higher in Crohn’s disease and remained elevated after anti-TNF-α treatment, although the treatment improved intestinal balance between IL-17+ effector and reg ...
... FOXP3+ cells than did control subjects, both before and after the anti-TNF-α treatment. Intestinal interferon-γ and IL-17 mRNA expression was higher in Crohn’s disease and remained elevated after anti-TNF-α treatment, although the treatment improved intestinal balance between IL-17+ effector and reg ...
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA
... even more substantiated in face of the elaborated research conducted by Flach et al. [25]. From their study, they concluded that aluminum based salts firmly bind to and alter the structure of lipids in the dendritic cells’ plasma membrane. The alteration in focal lipid composition results in phagocyt ...
... even more substantiated in face of the elaborated research conducted by Flach et al. [25]. From their study, they concluded that aluminum based salts firmly bind to and alter the structure of lipids in the dendritic cells’ plasma membrane. The alteration in focal lipid composition results in phagocyt ...
HIV-1 Envelope gp41 Is a Potent Inhibitor of Chemoattractant
... receptor superfamily have been identified as essential cofactors for HIV-1 entry (5), and HIV-1 cell-type tropism seems to be dictated by chemokine receptor usage. After the binding of the envelope gp120 to CD4, the chemokine receptors, CXCR4 for T lymphotropic and CCR5 for monotropic HIV-1, may eit ...
... receptor superfamily have been identified as essential cofactors for HIV-1 entry (5), and HIV-1 cell-type tropism seems to be dictated by chemokine receptor usage. After the binding of the envelope gp120 to CD4, the chemokine receptors, CXCR4 for T lymphotropic and CCR5 for monotropic HIV-1, may eit ...
Cancer immunotherapy
![](https://commons.wikimedia.org/wiki/Special:FilePath/Peptide_bound_to_Rituximab_FAB.png?width=300)
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.